ELTX

Elicio Therapeutics Inc

1.67

Oct 21 • 3:59 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Peers: GLSI IMMP PDSB EVAX GOVX ANIX HURA CRDF IMRX IMNN

| Held by: VTI IWM VXF IWO VTWO IWC VTWG RSSL ITWO URTY

Index	RUT
Market Cap	45.24M
Enterprise Value	35.91M
Income	-37.84M
Sales	0.00M
Book/sh	0.36
Cash/sh	0.87
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	33
IPO	Feb 05, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	4.61
P/C	1.93
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	2.77
Current Ratio	2.77
Debt/Eq	1.78
LT Debt/Eq	1.65
Option/Short	Yes / Yes

EPS (ttm)	-2.11
EPS next Y	-1.69
EPS next Q	-0.48
EPS this Y	27.07%
EPS next Y	10.13%
EPS next 5Y	22.95%
EPS past 3/5Y	85.75% 37.53%
Sales past 3/5Y	- -
EPS Y/Y TTM	49.43%
Sales Y/Y TTM	-
EPS Q/Q	35.07%
Sales Q/Q	-
Earnings	Aug 13 AMC
EPS/Sales Surpr.	20.00% -

Insider Own	27.95%
Insider Trans	0.00%
Inst Own	20.03%
Inst Trans	16.58%
ROA	-124.36%
ROE	-774.56%
ROIC	-180.09%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-7.20%
SMA50	-25.48%
SMA200	-76.14%
Trades

Shs Outstand	21.90M
Shs Float	19.52M
Short Float	7.95%
Short Ratio	5.08
Short Interest	1.55M
52W High	16.00 -89.56%
52W Low	1.44 15.97%
Volatility	10.82% 7.53%
ATR (14)	0.14
RSI (14)	34.44
Beta	1.64
Rel Volume	0.00
Avg Volume	305.88K
Volume	0

Perf Week	-6.70%
Perf Month	-10.70%
Perf Quarter	-46.98%
Perf Half Y	-86.06%
Perf YTD	-79.02%
Perf Year	-82.37%
Perf 3Y	-72.44%
Perf 5Y	-98.08%
Perf 10Y	-
Recom	1.40
Target Price	14.38
Prev Close	1.67
Price	1.67
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-18-26	Resumed	Ladenburg Thalmann	Buy	$12
Jun-10-26	Initiated	B. Riley Securities	Buy	$27
Apr-15-26	Initiated	Ladenburg Thalmann	Buy	$20
Mar-10-26	Initiated	Rodman & Renshaw	Buy	$17

Sep-24-26 08:00AM	Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026 (GlobeNewswire)
Aug-31-26 08:00AM	Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
Aug-24-26 08:00AM	Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference (GlobeNewswire)
Aug-13-26 04:26PM	Elicio Therapeutics: Q2 Earnings Snapshot (Associated Press)
04:01PM	Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
08:00AM	Loading…
Aug-10-26 08:00AM	Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
Jul-06-26 04:05PM	Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering (GlobeNewswire) -15.02%
Jul-02-26 07:22AM	Another Blow For ELTX? Elicio Raises Fresh Capital Weeks After Trial Disappointment (Stocktwits) -37.35%
12:25AM	Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering (GlobeNewswire)
Jun-29-26 08:00AM	Elicio Therapeutics Added to Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-17-26 08:00AM	Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer (GlobeNewswire) +70.65%
Jun-15-26 02:50PM	ELTX Stock Heads For Worst Day Ever Elicio Therapeutics' Pancreatic Cancer Data Disappoints (Stocktwits) -72.53%
09:45AM	Elicio Therapeutics Shares Plunge After Pancreatic Cancer Study Misses Main Goal (ELTX) (InvestorsHub)
07:00AM	Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer (GlobeNewswire)
Jun-01-26 08:00AM	Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company's AMP-DNA Adjuvant Technology (GlobeNewswire) +5.94%
04:17PM	Loading…
May-11-26 04:17PM	Elicio Therapeutics: Q1 Earnings Snapshot (Associated Press) +17.15% -9.13%
04:05PM	Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
Apr-30-26 08:00AM	Elicio Therapeutics to Present at the Bank of America Healthcare Conference (GlobeNewswire)
Apr-16-26 08:00AM	Elicio Therapeutics Reports Inducement Grants (GlobeNewswire) +6.96%
Mar-24-26 10:30AM	Advancements in Novel Immunotherapeutics in The Oncology Battle (Newsfile)
Mar-17-26 08:00AM	Elicio Therapeutics Reports Inducement Grants (GlobeNewswire)
Mar-12-26 06:09PM	Elicio Therapeutics: Q4 Earnings Snapshot (Associated Press Finance) -7.55% +11.93%
04:05PM	Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
Feb-25-26 08:00AM	Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference (GlobeNewswire) +10.35%
Feb-18-26 08:00AM	Elicio Therapeutics Reports Inducement Grants (GlobeNewswire)
Jan-16-26 08:00AM	Elicio Therapeutics Reports Inducement Grants (GlobeNewswire) +5.63%
Dec-23-25 09:40AM	Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-16-25 08:00AM	Elicio Therapeutics Reports Inducement Grants (GlobeNewswire)
Dec-11-25 12:00PM	Elicio Therapeutics (ELTX) Upgraded to Buy: Here's Why (Zacks)
08:00AM	Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial (GlobeNewswire)
08:00AM	Loading…
Nov-19-25 08:00AM	Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer (GlobeNewswire) -5.48%
Nov-13-25 04:09PM	Elicio Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
Nov-07-25 09:00AM	Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC (GlobeNewswire)
Nov-03-25 08:00AM	Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting (GlobeNewswire)
Oct-27-25 08:00AM	Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial (GlobeNewswire)
Sep-29-25 08:00AM	Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
Sep-18-25 08:00AM	Elicio Therapeutics Reports Inducement Grants (GlobeNewswire)
Sep-17-25 08:00AM	Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial (GlobeNewswire)
Aug-13-25 01:03PM	Elicios peptide cancer vaccine shows survival benefit in Phase I trial (Clinical Trials Arena)
Aug-12-25 08:00AM	Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease ("MRD") Positive, Adjuvant-Stage Patients (GlobeNewswire) +8.67%
Aug-07-25 04:39PM	Elicio Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:30PM	Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
Aug-05-25 07:00AM	Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis (GlobeNewswire) -7.96%
Jul-28-25 12:59PM	Unlocking Oncologys Future: 3 Trending Cancer Biotech Stocks with Strong Buy Ratings (Barchart)
Jun-17-25 08:00AM	Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer (GlobeNewswire)
Jun-04-25 08:00AM	Elicio Therapeutics Secures $10 Million in Financing (GlobeNewswire)
May-13-25 04:23PM	Elicio Therapeutics: Q1 Earnings Snapshot (Associated Press Finance) -5.25%
04:05PM	Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
May-01-25 09:55AM	Here's Why Elicio Therapeutics (ELTX) Could be Great Choice for a Bottom Fisher (Zacks)
Apr-16-25 04:05PM	Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires (GlobeNewswire)
Apr-04-25 09:40AM	Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year? (Zacks) +9.27%
Apr-03-25 12:00PM	Elicio Therapeutics (ELTX) Upgraded to Buy: Here's What You Should Know (Zacks) +6.38%
Mar-31-25 07:00AM	Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates (GlobeNewswire) -20.92%
Mar-24-25 07:00AM	Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer (GlobeNewswire)
Feb-03-25 07:15PM	Why Elicio Therapeutics Inc (ELTX) Is Skyrocketing So Far In 2025 (Insider Monkey)
Jan-30-25 08:00AM	Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Jan-22-25 07:30AM	Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy (GlobeNewswire) +15.81%
Dec-13-24 07:29AM	Elicio Therapeutics Advances ELI-002 and Secures Funding (TipRanks)
Dec-12-24 07:00AM	Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024 (GlobeNewswire) -6.20%
Dec-03-24 07:00AM	Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment (GlobeNewswire)
Nov-13-24 04:23PM	Elicio Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Nov-07-24 04:05PM	Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer ( SITC ) 2024 Annual Meeting (GlobeNewswire) +10.20%
Oct-31-24 08:30AM	Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit (GlobeNewswire)
Oct-24-24 12:00PM	All You Need to Know About Elicio Therapeutics (ELTX) Rating Upgrade to Strong Buy (Zacks)
Oct-16-24 08:30AM	Elicio Therapeutics Reports Inducement Grants (GlobeNewswire) +5.79%
Sep-17-24 08:31AM	Elicio Therapeutics Reports Inducement Grants (GlobeNewswire)
Sep-13-24 08:30AM	Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines (GlobeNewswire)
Aug-28-24 08:00AM	Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-13-24 04:30PM	Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire) -5.30%
Aug-12-24 04:05PM	Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note (GlobeNewswire)
Jun-28-24 09:00AM	Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering (GlobeNewswire) -40.35%
08:49AM	Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today? (InvestorPlace)
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-27-24 04:05PM	Elicio Therapeutics Announces Proposed Public Offering (GlobeNewswire) +6.99%
04:01PM	Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P (GlobeNewswire)
Jun-18-24 08:30AM	Elicio Therapeutics Reports Inducement Grants (GlobeNewswire) -10.90%
May-23-24 05:30PM	Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting (GlobeNewswire)
May-16-24 06:02AM	BayWa r.e. and Elicio to build 270MW floating wind farm in France (Power Technology) -9.81%
May-15-24 10:53PM	ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
04:30PM	Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Apr-25-24 08:30AM	Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-05-24 04:30PM	Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting (GlobeNewswire) +17.69%
Apr-02-24 07:53AM	ELTX Stock Earnings: Elicio Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
Mar-29-24 08:30AM	Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Mar-18-24 08:00AM	Elicio Therapeutics Announces $6.0 Million Private Placement Financing (GlobeNewswire) +28.00%
Mar-06-24 08:30AM	Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Feb-05-24 08:30AM	Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-25-24 09:00AM	Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors (GlobeNewswire) +16.67%
Jan-17-24 08:30AM	Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium (GlobeNewswire)
Jan-16-24 08:30AM	Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference (GlobeNewswire)
Jan-11-24 08:30AM	Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study (GlobeNewswire)
Jan-09-24 08:26AM	Why Is Elicio Therapeutics (ELTX) Stock Up 11% Today? (InvestorPlace) -30.31%
06:00AM	Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic's AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002 (GlobeNewswire)
Dec-22-23 09:00AM	Elicio Therapeutics Announces $7.0 Million Private Placement Financing (GlobeNewswire) +11.21%
Dec-04-23 08:00AM	Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference (GlobeNewswire) +11.04%
Nov-09-23 04:30PM	Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire) -18.76%
Nov-03-23 04:30PM	Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting (GlobeNewswire) +9.06%
Oct-11-23 08:00AM	Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC 2023) Annual Meeting (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DeMuth Peter	Chief Scientific Officer	Dec 09 '25	Option Exercise	4.41	362	1,596	743	Dec 10 05:05 PM

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. It focuses on its Amphiphile platform for trafficking lymph nodes. The company was founded by Darrell Irvine in August 2011 and is headquartered in Boston, MA.

CEOMr. Robert T. Connelly

FACPDr. Allen Richard Nissenson F.A.S.N.

Ph.D.Dr. Preetam Shah M.B.A.

Ph.D.Dr. Christopher M. Haqq M.D.

Co-FounderDr. Darrell J. Irvine Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ELTX

Elicio Therapeutics Inc

Upgrade your Finviz experience